ABT-199 (Venetoclax), the first BH3 mimetic approved to treat chronic lymphocytic leukemia (CLL) in 2016, specifically targets BCL2 [15,16,17]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.